MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells

Abstract

microRNA-221 (miRNA-221) is upregulated in several malignant tumors and is associated with poor patient prognosis. Therefore, the present study aimed to investigate the role and underlying mechanism of miRNA-221 in doxorubicin (DOX) resistance in osteosarcoma cells. We constructed DOX-resistant Saos-2/DOX cells and treated them with DOX. Cell viability was determined by performing an MTT assay. Cells were transfected with either miRNA-221 mimic or miRNA-221 inhibitor; real-time quantitative reverse transcription PCR was performed to detect the expression of miRNA-221. Flow cytometry and TUNEL staining were used to detect cell apoptosis. The immunofluorescence method was also used to detect cell Stat3 protein expression distribution. In addition, western blotting was used to detect changes in the expression of each protein. We found that miRNA-221 was upregulated in Saos-2/DOX cells. Moreover, the miRNA-221 mimic induced DOX resistance in Saos-2 cells, whereas the miRNA-221 inhibitor enhanced DOX sensitivity in Saos-2/DOX cells. The miRNA-221 mimic upregulated the expression of phosphorylated-Stat3, P-gp, and Bcl-2 proteins in Saos-2 cells and induced the entry of Stat3 into the nucleus, whereas the miRNA-221 inhibitor exerted the opposite effect. Pretreatment with the Stat3 chemical inhibitor, STAT3-IN-3, significantly inhibited the upregulation of P-gp and Bcl-2 protein expression induced by the miRNA-221 mimic in Saos-2 cells; it also caused the Saos-2 cells to overcome DOX resistance induced by the miRNA-221 mimic. Thus, miRNA-221 increased the expression of P-gp and Bcl-2 by activating the Stat3 pathway to promote DOX resistance in osteosarcoma cells, indicating a potential use of miRNA-221 in osteosarcoma treatment.

MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis

“…As we all know, miRNA usually exerts its function in repressing gene expression at post-transcription level [ 40 ]. However, other regulatory manners, such as transcriptional regulation via interacting with the promoter or cofactors of transcription factors in the nucleus is also been found [ 41 , 42 ]. Additionally, the different region of miRNA all can be involved in regulating target expression.…”

<i>Astragalus</i> Polysaccharide Suppresses Cell Proliferation and Invasion by Up-Regulation of miR-195-5p in Non-small Cell Lung Cancer

“…MiRNAs, binding to untranslated region located in 3′ tail (3′-UTR) of mRNA, modulate its function through the im- pact on translation process, therefore miRNAs regulate gene expression post-transcriptionally. 33,34) The expression of glycolytic enzyme Hexokinase 2 (HK2) was targeted regulated by miR-143-5p, which has been proved to be downregulated in lung cancer through excessive activation of mammalian target of rapamycin (mTOR) signalling pathway. 35) Similarly, the expression of miR-124-5p in NSCLC cells exerted its cancer suppressor function by decreasing lung cancer cell proliferation and migration.…”

Tumor-Infiltrating Lymphocytes and Cancer Markers in Osteosarcoma: Influence on Patient Survival

“…P-glycoprotein is a drug efflux pump and its overexpression by tumor cells has been implicated in multidrug resistance in several solid tumors [ 35 ]. In OST, p-glycoprotein has been associated with resistance to chemotherapy and it has been hypothesized that targeted therapy to p-glycoprotein could be of importance to overcome the chemotherapy resistance in OST [ 36 , 37 , 38 ]. When we explored the risk or protective value of the presence of each tumor marker, we observed that patients with p-glycoprotein expression had a higher chance of death occurrence, despite only presenting a statistical value close to the significance level.…”